IP Verse

Salts Or Co-Crystals Of 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)-Phenol - EP3656765

The patent EP3656765 was granted to Grnenthal on Apr 14, 2021. The application was originally filed on Jul 22, 2011 under application number EP19214275A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3656765

GRNENTHAL
Application Number
EP19214275A
Filing Date
Jul 22, 2011
Status
Granted And Under Opposition
Mar 12, 2021
Grant Date
Apr 14, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMM & WITTKOPPJan 14, 2022HAMM & WITTKOPPWITHDRAWN
PAJAROJan 14, 2022BIRD & BIRDWITHDRAWN
MSN LABORATORIES PVTJan 13, 2022HAMM & WITTKOPPADMISSIBLE
INSUD PHARMA SLJan 13, 2022AERAWITHDRAWN
KRAUS & LEDERER PARTGMBBJan 13, 2022KRAUS & LEDERER PARTGMBBWITHDRAWN
G L PHARMAApr 15, 2021SONN PATENTANWALTEWITHDRAWN

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0693475
DESCRIPTIONEP1439829
OPPOSITIONEP0693475
OPPOSITIONEP3377049
OPPOSITIONWO03035053
OPPOSITIONWO2006002886
OPPOSITIONWO2007128412
OPPOSITIONWO2008012047
OPPOSITIONWO2008128739
OPPOSITIONWO2012010316
OPPOSITIONWO2012051246
SEARCHEP0693475
SEARCHWO02067651

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CHEMICAL ABSTRACTS, Database accession no. 175591-23-8-
OPPOSITION- 266, "2.9.3. Dissolution test for solid dosage forms", 266, Council of Europe, European Pharmacopeia 6.0, (20070101), pages 266 - 276, XP055897999-
OPPOSITION- Anonymous, "Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry", U.S. Department of Health and Human Services Food and Drug Administration, (20180201), pages 1 - 4, XP055814449-
OPPOSITION- European Directorate For The Quality Of Medicines & Healthcare, "Tartaric acid", European Pharmacopoeia 7.0, (20100715), page 3038, XP055898004-
OPPOSITION- Fda, "NUCYNTAâ„¢ safely and effectively. See full prescribing information for NUCYNTAâ„¢. NUCYNTAâ„¢ (tapentadol) immediate-release oral tablets C-II", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20090301), pages 1 - 26, HIGHLIGHTS OF PRESCRIBING INFORMATION, (20220307), XP055898012-
OPPOSITION- "Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry", FDA, (201802), URL: https://www.fda.gov/files/drugs/published/Regulatory-Classification-of-Pharmaceutical-Co-Crystals.pdf055814449, XP055814449-
OPPOSITION- Rowe Raymond C, "Talc", Handbook of Pharmaceutical Excipients, P&P , (20090101), pages 731 - 732, XP055796481-
OPPOSITION- Stahl P H, Wermuth C G, "chapter 12: Monographs on acids and bases", Stahl P H, Wermuth C G, P. Heinrich Stahl; Camille G. Wermuth (eds.), Handbook of pharmaceutical salts : properties, selection, and use, Weinheim , WILEY-VCH , (20020101), pages 265 - 327, ISBN 978-3-906390-26-0, XP008145189-
OPPOSITION- Stahl P H, Wermuth C G, Stahl P H, Wermuth C G, P. Heinrich Stahl; Camille G. Wermuth (eds.), Handbook of pharmaceutical salts : properties, selection, and use, Weinheim , WILEY-VCH , (20020101), page 308, ISBN 978-3-906390-26-0, XP008145189-
OPPOSITION- "Tartaric acid", European Directorate for the Quality of Medicines & HealthCare, European Pharmacopoeia 7.0, (20100715), page 3038, XP055898004-
OPPOSITION- Wikipedia, "Wikipedia Weinsäure", (20210325), pages 1 - 7, URL: https://de.wikipedia.org/wiki/Weinsaure, (20220126), XP055884052-
OPPOSITION- E. GROTHE et al., "Solvates, Salts and Cocrystals: A Proposal for a feasible Classification System", Crystal Growth Des., (20160000), doi:10.1021/acs.cgd.6b00200, pages 3237 - 3243, XP055774647
OPPOSITION- S. BYRN et al., "Pharmaceutical solids: a strategic approach to regulatory considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, doi:10.1023/A:1016241927429, pages 945 - 954, XP055399407
OPPOSITION- ALMARSSON ET AL., "Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals reprepsent a new path to improved medicines.", Chemical Communications, Royal Society of Chemistry, UK, UK , (20040101), doi:10.1039/b402150a, ISSN 1359-7345, pages 1889 - 1896, XP002415977
OPPOSITION- A V Yadav, A. S. Shete, A. P. Dabke, P. V. Kulkarni And S. S. Sakhare, "Co-Crystals: A Novel Approach to Modify Physicochemical Properties of Active Pharmaceutical Ingredients", Indian Journal of Pharmaceutical Science, (20090701), doi:10.4103/0250-474X.57283, pages 359 - 370, XP055398519

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents